The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL

Weimin Ci, Jose M. Polo, Leandro Cerchietti, Rita Shaknovich, Ling Wang, Ning Yang Shao, Qian K. Ye, Pedro Farinha, Douglas E. Horsman, Randy D. Gascoyne, Olivier Elemento, Ari Melnick

Research output: Contribution to journalArticle

137 Citations (Scopus)

Abstract

The BCL6 transcriptional repressor is required for development of germinal center (GC) B cells and when expressed constitutively causes diffuse large B-cell lymphomas (DLBCLs). We examined genome-wide BCL6 promoter binding in GC B cells versus DLBCLs to better understand its function in these settings. BCL6 bound to both distinct and common sets of functionally related gene in normal GC cells versus DLBCL cells. Certain BCL6 target genes were preferentially repressed in GC B cells, but not DLBCL cells. Several such genes have prominent oncogenic functions, such as BCL2, MYC, BMI1, EIF4E, JUNB, and CCND1. BCL6 and BCL2 expression was negatively correlated in primary DLBCLs except in the presence of BCL2 translocations. The specific BCL6 inhibitor retro-inverso BCL6 peptidomimetic inhibitor-induced expression of BCL2 and other oncogenes, consistent with direct repression effects by BCL6. These data are consistent with a model whereby BCL6 can directly silence oncogenes in GC B cells and counterbalance its own tumorigenic potential. Finally, a BCL6 consensus sequence and binding sites for other physiologically relevant transcription factors were highly enriched among target genes and distributed in a pathway-dependent manner, suggesting that BCL6 forms specific regulatory circuits with other B-cell transcriptional factors.

Original languageEnglish (US)
Pages (from-to)5536-5548
Number of pages13
JournalBlood
Volume113
Issue number22
DOIs
StatePublished - 2009

Fingerprint

Germinal Center
Lymphoma, Large B-Cell, Diffuse
Oncogenes
B-Lymphocytes
Cells
Genes
Eukaryotic Initiation Factor-4E
Peptidomimetics
Consensus Sequence
Transcription Factors
Binding Sites
Genome
Networks (circuits)

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Ci, W., Polo, J. M., Cerchietti, L., Shaknovich, R., Wang, L., Shao, N. Y., ... Melnick, A. (2009). The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood, 113(22), 5536-5548. https://doi.org/10.1182/blood-2008-12-193037

The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. / Ci, Weimin; Polo, Jose M.; Cerchietti, Leandro; Shaknovich, Rita; Wang, Ling; Shao, Ning Yang; Ye, Qian K.; Farinha, Pedro; Horsman, Douglas E.; Gascoyne, Randy D.; Elemento, Olivier; Melnick, Ari.

In: Blood, Vol. 113, No. 22, 2009, p. 5536-5548.

Research output: Contribution to journalArticle

Ci, W, Polo, JM, Cerchietti, L, Shaknovich, R, Wang, L, Shao, NY, Ye, QK, Farinha, P, Horsman, DE, Gascoyne, RD, Elemento, O & Melnick, A 2009, 'The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL', Blood, vol. 113, no. 22, pp. 5536-5548. https://doi.org/10.1182/blood-2008-12-193037
Ci, Weimin ; Polo, Jose M. ; Cerchietti, Leandro ; Shaknovich, Rita ; Wang, Ling ; Shao, Ning Yang ; Ye, Qian K. ; Farinha, Pedro ; Horsman, Douglas E. ; Gascoyne, Randy D. ; Elemento, Olivier ; Melnick, Ari. / The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. In: Blood. 2009 ; Vol. 113, No. 22. pp. 5536-5548.
@article{98b824634a9e4f01bcf05f9da27579f9,
title = "The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL",
abstract = "The BCL6 transcriptional repressor is required for development of germinal center (GC) B cells and when expressed constitutively causes diffuse large B-cell lymphomas (DLBCLs). We examined genome-wide BCL6 promoter binding in GC B cells versus DLBCLs to better understand its function in these settings. BCL6 bound to both distinct and common sets of functionally related gene in normal GC cells versus DLBCL cells. Certain BCL6 target genes were preferentially repressed in GC B cells, but not DLBCL cells. Several such genes have prominent oncogenic functions, such as BCL2, MYC, BMI1, EIF4E, JUNB, and CCND1. BCL6 and BCL2 expression was negatively correlated in primary DLBCLs except in the presence of BCL2 translocations. The specific BCL6 inhibitor retro-inverso BCL6 peptidomimetic inhibitor-induced expression of BCL2 and other oncogenes, consistent with direct repression effects by BCL6. These data are consistent with a model whereby BCL6 can directly silence oncogenes in GC B cells and counterbalance its own tumorigenic potential. Finally, a BCL6 consensus sequence and binding sites for other physiologically relevant transcription factors were highly enriched among target genes and distributed in a pathway-dependent manner, suggesting that BCL6 forms specific regulatory circuits with other B-cell transcriptional factors.",
author = "Weimin Ci and Polo, {Jose M.} and Leandro Cerchietti and Rita Shaknovich and Ling Wang and Shao, {Ning Yang} and Ye, {Qian K.} and Pedro Farinha and Horsman, {Douglas E.} and Gascoyne, {Randy D.} and Olivier Elemento and Ari Melnick",
year = "2009",
doi = "10.1182/blood-2008-12-193037",
language = "English (US)",
volume = "113",
pages = "5536--5548",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "22",

}

TY - JOUR

T1 - The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL

AU - Ci, Weimin

AU - Polo, Jose M.

AU - Cerchietti, Leandro

AU - Shaknovich, Rita

AU - Wang, Ling

AU - Shao, Ning Yang

AU - Ye, Qian K.

AU - Farinha, Pedro

AU - Horsman, Douglas E.

AU - Gascoyne, Randy D.

AU - Elemento, Olivier

AU - Melnick, Ari

PY - 2009

Y1 - 2009

N2 - The BCL6 transcriptional repressor is required for development of germinal center (GC) B cells and when expressed constitutively causes diffuse large B-cell lymphomas (DLBCLs). We examined genome-wide BCL6 promoter binding in GC B cells versus DLBCLs to better understand its function in these settings. BCL6 bound to both distinct and common sets of functionally related gene in normal GC cells versus DLBCL cells. Certain BCL6 target genes were preferentially repressed in GC B cells, but not DLBCL cells. Several such genes have prominent oncogenic functions, such as BCL2, MYC, BMI1, EIF4E, JUNB, and CCND1. BCL6 and BCL2 expression was negatively correlated in primary DLBCLs except in the presence of BCL2 translocations. The specific BCL6 inhibitor retro-inverso BCL6 peptidomimetic inhibitor-induced expression of BCL2 and other oncogenes, consistent with direct repression effects by BCL6. These data are consistent with a model whereby BCL6 can directly silence oncogenes in GC B cells and counterbalance its own tumorigenic potential. Finally, a BCL6 consensus sequence and binding sites for other physiologically relevant transcription factors were highly enriched among target genes and distributed in a pathway-dependent manner, suggesting that BCL6 forms specific regulatory circuits with other B-cell transcriptional factors.

AB - The BCL6 transcriptional repressor is required for development of germinal center (GC) B cells and when expressed constitutively causes diffuse large B-cell lymphomas (DLBCLs). We examined genome-wide BCL6 promoter binding in GC B cells versus DLBCLs to better understand its function in these settings. BCL6 bound to both distinct and common sets of functionally related gene in normal GC cells versus DLBCL cells. Certain BCL6 target genes were preferentially repressed in GC B cells, but not DLBCL cells. Several such genes have prominent oncogenic functions, such as BCL2, MYC, BMI1, EIF4E, JUNB, and CCND1. BCL6 and BCL2 expression was negatively correlated in primary DLBCLs except in the presence of BCL2 translocations. The specific BCL6 inhibitor retro-inverso BCL6 peptidomimetic inhibitor-induced expression of BCL2 and other oncogenes, consistent with direct repression effects by BCL6. These data are consistent with a model whereby BCL6 can directly silence oncogenes in GC B cells and counterbalance its own tumorigenic potential. Finally, a BCL6 consensus sequence and binding sites for other physiologically relevant transcription factors were highly enriched among target genes and distributed in a pathway-dependent manner, suggesting that BCL6 forms specific regulatory circuits with other B-cell transcriptional factors.

UR - http://www.scopus.com/inward/record.url?scp=67049097382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67049097382&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-12-193037

DO - 10.1182/blood-2008-12-193037

M3 - Article

VL - 113

SP - 5536

EP - 5548

JO - Blood

JF - Blood

SN - 0006-4971

IS - 22

ER -